Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 8/20 | 0.41 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.39 |
| ▸ | SLC19A1 | P41440 | 1/20 | 0.39 |
| ▸ | SLC46A1 | Q96NT5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19929101 | 1.00 | TYMS (0.41) | TYMSFOLR1SLC19A1SLC46A1 | |
| SCHEMBL21343009 | 1.00 | TYMS (0.41) | TYMSFOLR1SLC19A1SLC46A1 | |
| SCHEMBL19929273 | 1.00 | TYMS (0.41) | TYMSFOLR1SLC19A1SLC46A1 | |
| SCHEMBL19929270 | 1.00 | TYMS (0.41) | TYMSFOLR1SLC19A1SLC46A1 | |
| SCHEMBL19929275 | 1.00 | TYMS (0.41) | TYMSFOLR1SLC19A1SLC46A1 | |
| SCHEMBL23005880 | 1.00 | TYMS (0.41) | TYMSFOLR1SLC19A1SLC46A1 | |
| SCHEMBL15972267 | 0.84 | PNP (0.32) | — | |
| Hydrochloric Acid SCHEMBL29354653 | 0.83 | PNP (0.32) | — | |
| SCHEMBL21343010 | 0.82 | TYMS (0.41) | TYMSFOLR1SLC19A1SLC46A1 | |
| SCHEMBL23109473 | 0.82 | TYMS (0.40) | TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4743093-A1 | METABOLITES FOR TRNA MODIFICATION | The University of Chicago (US) | 2026-05-20 | — | — | EP | claimed |
| WO-2025071519-A1 | A FORMULATION FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | T.C. USKUDAR UNIVERSITESI (TR) | 2025-04-03 | — | — | WO | claimed |
| WO-2025061911-A1 | METHODS OF PRODUCING NUCLEOTIDE TRIPHOSPHATES (NTPS) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-03-27 | — | — | WO | claimed |
| WO-2025015197-A1 | METABOLITES FOR TRNA MODIFICATION | THE UNIVERSITY OF CHICAGO (US) | 2025-01-16 | — | — | WO | claimed |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2024-05-02 | — | — | US | claimed |
| US-20230295165-A1 | COMPOUNDS | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2023-09-21 | — | — | US | claimed |
| US-20230286987-A1 | COMPOUNDS | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2023-09-14 | — | — | US | claimed |
| US-11684611-B2 | Compounds for treating diseases associated with a mitochondrial dysfunction | AMABIOTICS (FR) | 2023-06-27 | — | — | US | claimed |
| EP-4188932-A1 | COMPOUNDS | The Provost, Fellows, Foundation Scholars and the other members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth, (IE) | 2023-06-07 | — | — | EP | claimed |
| US-20110081675-A1 | Metabolic Biomarkers Of Drug-Induced Cardiotoxicity | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-04-07 | — | — | US | claimed |
| US-6596701-B1 | Identifying abnormalities in SAM pathways; screening; sampling | MEDIQUEST THERAPEUTICS, INC. | 2003-07-22 | — | — | US | claimed |
| US-20030078231-A1 | Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties | WILBURN MICHAEL D (US) | 2003-04-24 | — | — | US | claimed |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | WILBURN MICHAEL D (US) | 2003-01-09 | — | — | US | claimed |
| EP-1221615-A2 | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy | ORIDIGM CORPORATION (US) | 2002-07-10 | — | — | EP | claimed |
| US-6020139-A | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy | ORIDIGM CORPORATION (US) | 2000-02-01 | — | — | US | claimed |
| EP-0824345-A4 | S-ADENOSYL METHIONINE REGULATION OF METABOLIC PATHWAYS AND ITS USE IN DIAGNOSIS AND THERAPY | ORIDIGM CORP (US) | 1999-08-25 | — | — | EP | claimed |
| EP-0824345-A1 | S-ADENOSYL METHIONINE REGULATION OF METABOLIC PATHWAYS AND ITS USE IN DIAGNOSIS AND THERAPY | ORIDIGM CORPORATION (US) | 1998-02-25 | — | — | EP | claimed |
| WO-1996033703-A2 | S-ADENOSYL METHIONINE REGULATION OF METABOLIC PATHWAYS AND ITS USE IN DIAGNOSIS AND THERAPY | ORIDIGM CORPORATION (US) | 1996-10-31 | — | — | WO | claimed |
| US-5312900-A | Polypeptides | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1994-05-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295165-A1 | COMPOUNDS | NR3C1, NR3C2, CBR3 | TYMS 4575/4885FOLR1 1089/4885SLC19A1 3576/4885 |
| US-20030078231-A1 | Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties | MAT1A, LPO, TPMT | TYMS 1249/4885FOLR1 3252/4885SLC19A1 1833/4885 |
| US-20230286987-A1 | COMPOUNDS | HAX1, NHERF1, CXCR1 | TYMS 4374/4885FOLR1 2073/4885SLC19A1 2488/4885 |
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | HAVCR2, NR1H4, NR1H3 | TYMS 2697/4885FOLR1 1186/4885SLC19A1 1979/4885 |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | RBP4, RBP1, VDR | TYMS 4689/4885FOLR1 3463/4885SLC19A1 3262/4885 |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | SLC10A1, HAVCR2, HDGF | TYMS 940/4885FOLR1 1257/4885SLC19A1 185/4885 |
| US-11684611-B2 | Compounds for treating diseases associated with a mitochondrial dysfunction | NDUFAB1, FH, TFAM | TYMS 3412/4885FOLR1 3377/4885SLC19A1 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.